Bedrijfsprofiel Agendia
Bedrijfsnaam:
Agendia BV
Vestigingsplaats:
Amsterdam, Science Park 406, 1098 XH Amsterdam
Number of employees:
<46 (in Amsterdam)
About Agendia:
Agendia is a young company in the emerging field of biotechnology and a world leader in gene expression analysis-based diagnostics. Agendia is one of the few companies in the world to use micro array technology for clinical diagnostics purposes. We are part of the changing field of medicine moving towards personalised medicine. By analysing the genetic properties of a tumour, Agendia is able to unlock essential information about a patient’s risks of cancer recurrence and spread, response to chemotherapy or primary location of an unknown tumour. This information can assist oncologists and physicians to design individualised treatment plans which may enhance a patient’s prognosis. Agendia is an enthusiastic and fast growing organisation, focused on quality results, scientific initiative and improving patient prognosis.
Agendia is committed to improving the quality of life of people suffering from cancer through enabling effective personalized medicine.
Established in 2003, Agendia has already introduced three tests to the market. Since 2003, the DiscoverPrint service has been offered to pharmaceutical companies focusing on the development of cancer therapeutics, enabling them to select the most appropriate candidates for clinical trials of personalized therapeutics.
In 2004, Agendia became the first company to commercialize a prognostic test that predicts the risk of breast cancer recurrence (MammaPrint). The company also introduced CupPrint, a test to identify the origin of a metastasis when the location of the primary tumor is unknown, so called “Cancer of Unknown Primary”.
In 2007, MammaPrint became the first in vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire clearance from the US Food and Drug Administration (FDA). Agendia recently presented its new colon cancer prognosis profile, ColoPrint, which is currently undergoing further validation in the anticipation of developing a test to predict the likelihood of the cancer spreading at an early stage in the disease.
In 2008, Agendia launches its diagnostic test TargetPrint for breast cancer patients, which allows to obtain highly reliable quantitative data about each patients breast tumor and adds a secure prognostic tool for future treatment.
Careers and internships:
Agendia is a dynamic, innovative and rapidly growing molecular diagnostics company offering products based on unique technologies. The company has focused throughout its history on its core values of excellence in research and development and laboratory standards, collaboration and standardization, integrity, responsibility and accountability, trust, respect and entrepreneurship.
If you are dynamic, enthusiastic, highly motivated and believe that you can contribute to the further success of Agendia, then we’d like to hear from you. If you have experience from, or if you are interested in working (or doing an internship) in research and development, business development or marketing & sales within the biotechnology or pharmaceutical industry, please contact us.
On behalf of Agendia Dr Annuska Glas, Sr Director of R&D, will be present. Annuska has been working for Agendia since November 2003, building and shaping the R&D department which currently has 11 employees.
